These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12218315)

  • 1. Renal prostacyclin biosynthesis in a baboon model of Shiga toxin mediated hemolytic uremic syndrome.
    Siegler RL; Pysher TJ; Tesh VL; Taylor FB
    Nephron; 2002 Oct; 92(2):363-8. PubMed ID: 12218315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome.
    Pysher TJ; Siegler RL; Tesh VL; Taylor FB
    Pediatr Dev Pathol; 2002; 5(5):472-9. PubMed ID: 12196894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome.
    Siegler RL; Pysher TJ; Lou R; Tesh VL; Taylor FB
    Am J Nephrol; 2001; 21(5):420-5. PubMed ID: 11684808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.
    Siegler RL; Obrig TG; Pysher TJ; Tesh VL; Denkers ND; Taylor FB
    Pediatr Nephrol; 2003 Feb; 18(2):92-6. PubMed ID: 12579394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipopolysaccharide upregulates renal shiga toxin receptors in a primate model of hemolytic uremic syndrome.
    Clayton F; Pysher TJ; Lou R; Kohan DE; Denkers ND; Tesh VL; Taylor FB; Siegler RL
    Am J Nephrol; 2005; 25(6):536-40. PubMed ID: 16179829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS).
    Siegler RL; Pysher TJ; Tesh VL; Noris M; Cassis P; Taylor FB
    Ren Fail; 2005; 27(5):635-41. PubMed ID: 16153006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome.
    Siegler RL; Pysher TJ; Tesh VL; Taylor FB
    J Am Soc Nephrol; 2001 Jul; 12(7):1458-1467. PubMed ID: 11423574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin.
    Ikeda M; Ito S; Honda M
    Pediatr Nephrol; 2004 May; 19(5):485-9. PubMed ID: 15007712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice.
    Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Ohara S; Sato M; Hosoya M
    Nephrol Dial Transplant; 2015 Jun; 30(6):969-77. PubMed ID: 25694534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro prostacyclin production in the hemolytic-uremic syndrome.
    Siegler RL; Smith JB; Lynch MB; Mohammad SF
    West J Med; 1986 Feb; 144(2):165-8. PubMed ID: 3754077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome.
    Siegler RL; Pysher TJ; Tesh VL; Denkers ND; Taylor FB
    Pediatr Nephrol; 2002 Dec; 17(12):1053-8. PubMed ID: 12478357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis of renal tubular cells in Shiga-toxin-mediated hemolytic uremic syndrome.
    Kaneko K; Kiyokawa N; Ohtomo Y; Nagaoka R; Yamashiro Y; Taguchi T; Mori T; Fujimoto J; Takeda T
    Nephron; 2001 Feb; 87(2):182-5. PubMed ID: 11244315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LPS-primed CD11b
    Niu S; Paluszynski J; Bian Z; Shi L; Kidder K; Liu Y
    Sci Rep; 2018 Mar; 8(1):3994. PubMed ID: 29507316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shiga toxin-1 regulation of cytokine production by human proximal tubule cells.
    Hughes AK; Stricklett PK; Kohan DE
    Kidney Int; 1998 Oct; 54(4):1093-106. PubMed ID: 9767525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostacyclin in endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice.
    Wang W; Zolty E; Falk S; Summer S; Stearman R; Geraci M; Schrier R
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1131-6. PubMed ID: 17652370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.
    Taylor FB; Tesh VL; DeBault L; Li A; Chang AC; Kosanke SD; Pysher TJ; Siegler RL
    Am J Pathol; 1999 Apr; 154(4):1285-99. PubMed ID: 10233866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of shigatoxin-1 on arachidonic acid release by human glomerular epithelial cells.
    Schmid DI; Kohan DE
    Kidney Int; 2001 Sep; 60(3):1026-36. PubMed ID: 11532097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-keto-PGF1 alpha levels and prostacyclin therapy in 2 adult patients with hemolytic-uremic syndrome.
    Hautekeete ML; Nagler JM; Cuykens JJ; Parizel G; Laekeman GM; Herman AG
    Clin Nephrol; 1986 Sep; 26(3):157-9. PubMed ID: 3533335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome.
    Uchida H; Kiyokawa N; Horie H; Fujimoto J; Takeda T
    Pediatr Res; 1999 Jan; 45(1):133-7. PubMed ID: 9890621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.